Gestational Diabetes Diagnosis
Gestational diabetes should be diagnosed using a 75-gram, 2-hour oral glucose tolerance test (OGTT) performed at 24-28 weeks gestation, with diagnosis made if any one of the following plasma glucose thresholds is met or exceeded: fasting ≥92 mg/dL (5.1 mmol/L), 1-hour ≥180 mg/dL (10.0 mmol/L), or 2-hour ≥153 mg/dL (8.5 mmol/L). 1
Diagnostic Approach
Early Pregnancy Screening (First Trimester)
For women at high risk, universal testing should be performed at the first prenatal visit (before 13 weeks gestation) using:
- Fasting plasma glucose
- HbA1c, or
- Random plasma glucose 1
High-risk criteria include:
- Previous gestational diabetes
- Prior macrosomic infant (>4,500 g)
- Obesity or metabolic syndrome
- History of stillbirth or recurrent pregnancy loss
- Age >45 years
- Vascular disease
- Clinical symptoms of diabetes (e.g., glucosuria) 2
If early screening shows HbA1c ≥6.5% (≥48 mmol/mol), diagnose as overt diabetes in pregnancy, not gestational diabetes. This requires management as pre-existing diabetes. 3
Women with HbA1c 6.0-6.4% (42-47 mmol/mol) or previous gestational diabetes should undergo a 75-gram OGTT before 20 weeks gestation, ideally at 10-14 weeks. 3
Standard Screening (24-28 Weeks)
All pregnant women without previously diagnosed diabetes must undergo a 75-gram, 2-hour OGTT at 24-28 weeks gestation. 1 This is the critical diagnostic window based on the landmark HAPO study, which demonstrated continuous associations between maternal glucose levels and adverse pregnancy outcomes. 4, 5
IADPSG Diagnostic Criteria (International Standard)
The International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria, endorsed by the Endocrine Society, represent the most evidence-based approach 1:
Gestational Diabetes Diagnosis (any ONE abnormal value):
- Fasting: 92-125 mg/dL (5.1-6.9 mmol/L)
- 1-hour: ≥180 mg/dL (10.0 mmol/L)
- 2-hour: 153-199 mg/dL (8.5-11.0 mmol/L)
Overt Diabetes in Pregnancy (requires confirmation on separate day if asymptomatic):
- Fasting: ≥126 mg/dL (7.0 mmol/L)
- 2-hour: ≥200 mg/dL (11.1 mmol/L)
- HbA1c: ≥6.5% (≥48 mmol/mol) 1
Critical Implementation Details
Testing must use laboratory-analyzed plasma glucose, not capillary blood glucose from a meter. 1 This is a common pitfall that can lead to diagnostic errors.
The IADPSG criteria require only one abnormal value to diagnose gestational diabetes, unlike older two-step approaches requiring two abnormal values. 4, 5 This single-threshold approach eliminates confusion when encountering isolated elevated values and is based on continuous risk relationships demonstrated in the HAPO study.
Evidence Strength and Rationale
These criteria are derived from the HAPO study of over 23,000 pregnancies, which demonstrated that maternal glucose levels show continuous, graded associations with adverse outcomes including large-for-gestational-age infants, primary cesarean section, neonatal hypoglycemia, and elevated cord C-peptide. 4, 5 The thresholds were set at odds ratios of 1.75 for these outcomes.
Recent 2025 Australasian guidelines have proposed slightly higher thresholds (fasting ≥5.3 mmol/L, 1-hour ≥10.6 mmol/L, 2-hour ≥9.0 mmol/L) 3, but the IADPSG criteria remain the international standard endorsed by major endocrine and diabetes organizations. 1
Common Pitfalls
- Using capillary glucose instead of venous plasma glucose leads to inaccurate results
- Requiring two abnormal values (older criteria) will miss cases
- Skipping early screening in high-risk women delays diagnosis of overt diabetes
- Confusing gestational diabetes with overt diabetes - the latter requires different management and confirmation testing
- Failing to perform universal screening at 24-28 weeks - selective screening misses significant numbers of cases 6
Global Variation
While diagnostic criteria vary internationally (prevalence ranges from 7.4% to 23.8% depending on criteria used 7), the IADPSG approach provides pregnancy outcome-based thresholds and enables consistent global communication among clinicians and researchers. 4, 5